November 3, 2026
Digistain has been nominated for the EIT Awards 2026 in the Venture Award category. The Venture Award recognises organisations combining strong commercial potential with meaningful real-world […]
November 3, 2026
In September 2026 Sasha Becejac, Digistain’s CCO, was invited to speak at On Targeted Molecular Oncology 2026 in Ankara, Türkiye, sharing the latest developments around Digistain […]
November 3, 2026
In September 2026 Sarah Bond, our COO for the MENA region, took part in The Future Health Dialogue roundtable hosted at Hub71 in Abu Dhabi, alongside […]
November 3, 2026
In July 2026 co-founder Professor Chris Phillips and COO Sabrina Ali met clinicians, researchers and pathology teams at major hospitals and innovation centres in Shanghai, including […]
November 3, 2026
In March 2026 we announced that Digistain has secured the rights to distribute geneType® across Southeast Asia. geneType is developed by Rhythm Biosciences, a publicly listed […]
November 3, 2026
In March 2026 Digistain was represented at the Thailand Board of Investment roundtable at the Thai Embassy in London. The evening brought together leaders from healthcare, […]
November 3, 2026
In February 2026 Digistain was selected as one of 27 companies by the EUREKA Investment Readiness Network to join a mission to South Summit Brazil, held […]
November 3, 2026
In December 2025 we showcased Digistain at BIGOSA 2025 alongside our partner, the Key Oncologics team. We engaged with hundreds of delegates and shared our latest […]
October 6, 2025
In our ongoing effort to bring accessible cancer diagnostics to the regions that need them most, we are proud to announce the official launch of Digistain’s […]